Phase II efficacy and safety of Taro pharmaceuticals' pro-drug T2000 (1,3-dimethoxymethyl-5,5-diphenyl-barbituric acid) in patients with myoclonus dystonia: an open label sequential dose escalation study
Phase of Trial: Phase II
Latest Information Update: 26 Dec 2013
At a glance
- Drugs T 2000 (Primary)
- Indications Dystonia
- Focus Therapeutic Use
- Sponsors Taro Pharmaceuticals USA
- 25 Oct 2011 Planned end date changed from 1 Sep 2011 to 1 Oct 2011 as reported by ClinicalTrials.gov.
- 25 Oct 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 26 Nov 2010 Planned End Date changed from 1 Mar 2011 to 1 Sep 2011.